Michelle MacDonald sits down with Leigh Baxt, a practicing preclinical drug development scientist, for a rare episode that replaces peptide mystique with process. Baxt walks through the actual FDA approval pipeline—from preclinical toxicology through Phase III efficacy and NDA review—and uses it as a scalpel to dissect the current peptide landscape. The core message is stark: 99% of drug candidates fail after entering human trials, yet the peptides dominating social media (BPC-157 chief among them) haven't even reached that starting line. Listeners learn why BPC-157, despite its cult following in biohacking and bodybuilding circles, has no IND application, no registered clinical trial, no peer-reviewed human pharmacokinetic data, and no sponsor willing to carry it through the regulatory gauntlet. Baxt explains the drug interaction problem inherent in peptide stacking—when users combine three, five, or more compounds simultaneously, adverse event attribution becomes impossible, turning individual biology into an uncontrolled experiment. The conversation then shifts to agency: rather than relying on influencers or vendor marketing, listeners can verify any peptide claim independently using ClinicalTrials.gov, searching for registered trials, sponsor names, and phase designations. Baxt offers a concrete evaluation rubric: patent ownership, credible sponsor, published toxicology package, human PK/PD data, and peer-reviewed journal presence. The episode closes by addressing why peptide researchers themselves often abandon promising candidates—toxicity signals that emerge only in GLP toxicology studies, long after the initial excitement phase. For anyone allocating money, time, or biology to peptides, this episode provides the filter that separates lab curiosities from actual therapeutics.
Key Insights
- 99% of drugs that enter Phase I clinical trials never reach approval; most peptides discussed online haven't even cleared preclinical toxicology, placing them firmly in the "lab compound" category rather than therapeutic territory.
- BPC-157 is frequently described as "FDA-approved" by influencers, but it has no Investigational New Drug (IND) application, no registered clinical trial, and no legitimate route to human use outside of raw chemical distribution.
- Peptide stacking introduces a combinatorial risk profile that makes adverse event attribution impossible—when users inject 3-5 peptides simultaneously, no one can determine which compound caused a side effect or drug interaction.
- The single most reliable tool for independent verification is ClinicalTrials.gov: if a compound lacks a registered trial with a sponsor and a phase designation, all efficacy claims are extrapolation from animal or in vitro work.
- FDA approval is not a binary event but a multi-year sequence (preclinical IND → Phase I safety → Phase II dosing → Phase III efficacy → NDA review), and skipping stages signals either regulatory misrepresentation or illegal compounding.
- Leigh Baxt provides a repeatable evaluation framework: ask who holds the patent, whether a credible sponsor exists, what the toxicology package looks like, and whether human pharmacokinetic data is published in a peer-reviewed journal.
Who should listen: Investors and operators evaluating longevity or performance-enhancement compounds who need a repeatable due diligence framework grounded in regulatory reality rather than influencer marketing.
Why This Matters
We track decision infrastructure, not just assets. This episode maps directly to our principle that due diligence requires understanding the regulatory pipeline before allocating capital or adopting a protocol—peptides are no different from any other early-stage technology where signaling outpaces substance.
